BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
🔮 Pre-Market Download
The "Dilution Divergence" & A Prostate Cancer Win: Wednesday’s trading session highlighted a critical shift in institutional sentiment: Biotech financing is back, but the market is discriminating.
The Winner: Kodiak Sciences (KOD) upsized its offering to $160M and the stock rallied +11.7%. Investors are hungry for late-stage, high-conviction assets.
Meanwhile, Pfizer (PFE) continued its slide (-1.9%) as Wall Street digests the soft 2026 guidance, and the FDA handed out a full approval in prostate cancer to a post-bankruptcy asset.
Market Watch: Recursion (RXRX) bounced +11.4% yesterday as AI-bio sentiment stabilized.
💉 Top Stories
Kodiak Sciences (KOD) Defies Gravity: Typically, secondary offerings crush biotech stocks. Yesterday, Kodiak upsized its raise to $160M at $23.00/share, and the stock closed near $27.00. The "oversubscribed" deal for its Phase 3 retina pipeline signals that deep-pocketed funds are deploying cash into late-stage readouts for 2026. 👉 Read more
FDA Grants Full Approval to Rubraca: The FDA converted the accelerated approval of Rubraca (rucaparib) to full approval for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Pharmaand GmbH (which acquired the asset from the bankrupt Clovis Oncology) scored the regulatory win based on the TRITON3 trial showing a significant radiographic progression-free survival benefit. 👉 Read more
Immunome (IMNM) Punished on Pricing: Despite the positive desmoid tumor data earlier in the week, Immunome shares tanked -15% after pricing a massive $400M offering. The sheer size of the dilution outweighed the clinical win, a reminder that "valuation discipline" has returned.
Capricor (CAPR) Webinar Reaction: Following its 1:00 PM ET webinar on the Phase 3 HOPE-3 data, Capricor saw elevated volume. Management reinforced the "disease modifying" potential of deramiocel in Duchenne Muscular Dystrophy, aiming to file a BLA promptly. The stock remains a battleground over the commercial ramp speed. 👉 Read more
🔬 Clinical Pulse
📊 Market Snapshot (Wednesday Close)
Ticker | Close | Change | Note |
KOD | $26.97 | +11.8% | Upsized offering digested aggressively. |
RXRX | $4.68 | +11.4% | Technical bounce off support. |
PFE | $25.04 | -1.9% | New lows on "Guidance Reset". |
IMNM | $19.78 | -15.8% | Dilution hangover from $400M raise. |
🔒 New for 2026: The Full Catalyst Calendar is now live for Pro subscribers.
Your forward-looking playbook, every major PDUFA, Phase 3 readout, and conference catalyst mapped for the year ahead. View the 2026 Catalyst Calendar
🛑 Access Restricted: You’ve Reached the End of the Free Brief
Join 5,000+ industry leaders (from Pfizer, J&J, and Top Tier VCs) who use BioMed Nexus Pro to spot shifting standards of care and market catalysts before they happen.
Unlock Full AccessUnlock the full institutional briefing instantly:
- The Deal Room: Exclusive strategic analysis, M&A rumors, and valuation drivers not found in the general press.
- Catalyst & Impact Matrix: Our proprietary "Regulatory Verdict" on every major upcoming PDUFA and Phase 3 readout.
- The Strategist's Notebook: High-conviction market analysis and forward-looking trends for the week ahead.